Submitted:
17 October 2024
Posted:
18 October 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Mohamadian M, Chiti H, Shoghli A, Biglari S, Parsamanesh N, Esmaeilzadeh A. COVID-19: Virology, biology and novel laboratory diagnosis. J Gene Med. 2021 Feb;23(2): e3303. [CrossRef]
- Mosquera-Sulbaran JA, Pedreañez A, Carrero Y, Callejas D. C-reactive protein as an effector molecule in Covid-19 pathogenesis. Rev Med Virol. 2021 Nov;31(6): e2221. [CrossRef]
- Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). Vol. 251, Journal of Pathology. 2020. p. 228–48. [CrossRef]
- Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. Vol. 92, Journal of Medical Virology. 2020. p. 726–30. [CrossRef]
- Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res. 2020 Jul;43(7):648–54. [CrossRef]
- Bannaga AS, Tabuso M, Farrugia A, Subashini Chandrapalan S, Karenjit Somal K, Voon Kune Lim VK, Shahd Mohamed S, et al. C-reactive protein and albumin association with mortality of hospitalised SARS-CoV-2 patients: a tertiary hospital experience. Clin Med. 2020;20: 463-467. [CrossRef]
- Cillóniz C, Torres A, Garcia-Vidal C, Estela Moreno-Garcia E, Rosanel Amaro R, Nestor Soler N, et al. The value of C-reactiv protein-to-lymphocyte ratio in predicting the severity of SARSCoV-2 pneumonia. Arch Bronconeumol. 2020; S0300- 2896:30277-30285. [CrossRef]
- Torzewski J, Heigl F, Zimmermann O. First-in-Man: case report of selective C- reactive protein apheresis in a patient with SARS-CoV-2 infection. Am J Case Rep. 2020;21: e925020. [CrossRef]
- Baumeister D, Akhtar R, Ciufolini S, Pariante CM, Mondelli V. Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, inetleukin- 6 and tumour necrosis factor-α. Mol Psychiatry. 2016; 21:642-649. [CrossRef]
- Mosquera-Sulbaran J, Pedreañez A, Carrero Y, Callejas D. C-reactive protein as an effector molecule in the COVID-19 pathogenesis. Reviews in Medical Virology. 2021; 1-8, e2221. [CrossRef]
- RodOviedo- Trespalacios JEO, Cortes-Ramirez J. A brief-review of the risk factors for covid-19 severity. Rev Saude Publica. 2020; 54:60. [CrossRef]
- Luo X, Zhou W, Yan X, Tangxi Guo T, Benchao Wang B, Hongxia Xia H, et al. Prognostic value of C-reactive protein in patients with COVID-19. Clin Infect Dis. 2020: ciaa641. [CrossRef]
- Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020; 50:332-33434. [CrossRef]
- Shiny A, Bibin YS, Shanthirani CS, Regin BS, Anjana RM, Balasubramanyam M, et al. Association of neutrophil-lymphocyte ratio with glucose intolerance: an indicator of systemic inflammation in patients with type 2 diabetes. Diabetes Technol Ther. 2014 Aug;16(8):524–30. [CrossRef]
- Balta S, Celik T, Mikhailidis DP, Ozturk C, Demirkol S, Aparci M, Iyisoy A. The Relation Between Atherosclerosis and the Neutrophil-Lymphocyte Ratio. Clin Appl Thromb Hemost. 2016; 22:405-411. [CrossRef]
- Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta- analysis. J Med Virol 2020. [CrossRef]
- Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18: 206. [CrossRef]
- Chen X, Zhang SX, Jahanshahi AA, Alvarez-Risco A, Dai H, Li J, Ibarra VG. Belief in a COVID-19 Conspiracy Theory as a Predictor of Mental Health and Well-Being of Health Care Workers in Ecuador: Cross-Sectional Survey Study. JMIR Public Health Surveill. 2020;6(3): e20737. /: https. [CrossRef]
- Cañizares Fuentes R, Aroca R, Blasco Carlos M. Evaluation of COVID- 19 Surveillance Strategy in Ecuador. Disaster Med Public Health Prep. 2020; 9:1-4. /: https. [CrossRef]
- Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: im-plications for virus origins and receptor binding. Lancet (London, England). 2020 Feb;395(10224):565–74.
- Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Jul;75(7):1730–41. [CrossRef]
- Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. J Med Virol. 2020 Oct;92(10):1902–14. [CrossRef]
- Pedreáñez A, Mosquera-Sulbarán J, Robalino J, Tene D, Muñóz N. Elevación del índice neutrófilo/linfocito y su relación con la proteína C reactiva en pacientes con diabetes mellitus tipo 2. Rev la Soc Argentina Diabetes. 2021;55(3):77–83.
- Mousavi-Nasab SD, Mardani R, Nasr Azadani H, Zali F, Ahmadi Vasmehjani A, Sabeti S, et al. Neutrophil to lymphocyte ratio and C-reactive protein level as prognostic markers in mild versus severe COVID-19 patients. Gastroenterol Hepatol from bed to bench. 2020;13(4):361–6.
- Yufei Y, Mingli L, Xuejiao L, Xuemei D, Yiming J, Qin Q, et al. Utility of the neutrophil-to-lymphocyte ratio and C-reactive protein level for coronavirus disease 2019 (COVID-19). Scand J Clin Lab Invest. 2020 Nov;80(7):536–40. [CrossRef]
- Liu Y, Liao W, Wan L, Xiang T, Zhang W. Correlation between relative nasopharyngeal virus RNA load and lymphocyte count disease severity in patients with COVID-19. Viral Immunol. 2021;34(5):330–5. [CrossRef]
- Fathi N, Rezaei N. Lymphopenia in COVID-19: Therapeutic opportunities. Cell Biol Int. 2020 Sep;44(9):1792–7. [CrossRef]
- Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2020 Jun; 127:104370. [CrossRef]
- Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020 Dec;9(1):1123–30. [CrossRef]
- Gómez-de-Segura GD, González MO, Pedraza MA. Asociación de marcadores inflamatorios en COVID-19 severo al ingreso con mortalidad y disfunción orgánica. Med Crit. 2023;37(4):276-290. [CrossRef]
- Yamada T, Wakabayashi M, Yamaji T, Chopra N, Mikami T, Miyashita H, et al. Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis. Clin Chim Acta. 2020 Oct; 509:235–43. [CrossRef]
- Tatum D, Taghavi S, Houghton A, Stover J, Toraih E, Duchesne J. Neutrophil-to-Lymphocyte Ratio and Outcomes in Louisiana COVID-19 Patients. Shock. 2020 Nov;54(5):652–8. [CrossRef]
- Sayed AA, Allam AA, Sayed AI, Alraey MA, Joseph M V. The use of neutrophil-to-lymphocyte ratio (NLR) as a marker for COVID-19 infection in Saudi Arabia: A case-control retrospective multicenter study. Saudi Med J. 2021 Apr;42(4):370–6. [CrossRef]
- Bedel C, Korkut M, Armağan HH. Comment on '"Can the neutrophil/lymphocyte ratio (NLR) have a role in the diagnosis of coronavirus 2019 disease (COVID-19)?"' Rev Assoc Med Bras. 2021;67(Suppl 1):168–9. [CrossRef]
- Bedel C, Korkut M. Neutrophil-to-Lymphocyte Ratio and Covid-19. Shock [Internet]. 2021 Nov;56(5):874. Available from: https://journals.lww.com/10.1097/SHK.0000000000001712.
| All patients | Deceased | Survivors | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Parameters | X±SD | Min value | Max value | X±SD | Min value | Max value | X±SD | Min value | Max value | P values |
| Age (years) | 53.68±16.61 | 16 | 86 | 54.58± 16.42 | 18 | 86 | 52.91± 17.12 | 16 | 84 | NS |
| Neutrophils (K/µL) | 12.16±5.78 | 3.11 | 23.65 | 9.35±5.32 | 3.11 | 23.65 | 14.58±5.10 | 3.51 | 19.34 | 0.003 |
| Lymphocytes (K/µL) | 4.40±3.24 | 0.22 | 11.0 | 1.49± 0.90 | 0.22 | 3.05 | 6.90± 2.26 | 1.84 | 11.02 | < .001 |
| NLR | 6.44±11.95 | 1.12 | 75.23 | 11.29±16.43 | 1.21 | 75.23 | 2.25±1.13 | 1.13 | 6.68 | 0.028 |
| CRP (mg/L) | 51.73±29.86 | 12.0 | 96.0 | 30.02± 21.50 | 13.0 | 77.0 | 71.38±21.66 | 12.0 | 96.0 | < .001 |
| Variables | AGE | Neutrophils (K/µL) | Lymphocytes (K/µL) | NLR | CRP (mg/L) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| r value | p-value | r value | p-value | r value | p-value | r value | p-value | r value | p-value | |
| AGE | - | - | ||||||||
| Neutrophils (K/µL) | 0.115 | 0.639 | - | - | ||||||
| Lymphocytes (K/µL) | 0.544* | 0.016 | -0.104 | 0.673 | - | - | ||||
| NLR | 0.520* | 0.023 | 0.493* | 0.032 | -0.538 | 0.017 | - | - | ||
| CRP (mg/L) | 0.382 | 0.106 | 0.086 | 0.725 | -0.011 | 0.966 | 0.025 | 0.920 | - | - |
| Variables | AGE | Neutrophils (K/µL) | Lymphocytes (K/µL) | NLR | CRP (mg/L) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| r value | p-value | r value | p-value | r value | p-value | r value | p-value | r value | p-value | |
| AGE | - | - | ||||||||
| Neutrophils (K/µL) | 0.521* | 0.013 | - | - | ||||||
| Lymphocytes (K/µL) | 0.690*** | <0.001 | 0.645* | 0.001 | - | - | ||||
| NLR | 0.299 | 0.176 | 0.321 | 0.146 | -0.400 | 0.065 | - | - | ||
| CRP (mg/L) | 0.715*** | <0.001 | 0.593** | 0.004 | 0.797*** | <0.001 | 0.330 | 0.134 | - | - |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).